Capricor Therapeutics Stock Today
| CAPR Stock | USD 19.04 0.02 0.10% |
Performance18 of 100
| Odds Of DistressLess than 36
|
Capricor Therapeutics is selling at 19.04 as of the 28th of November 2024; that is 0.1 percent decrease since the beginning of the trading day. The stock's lowest day price was 18.67. Capricor Therapeutics has about a 36 percent probability of financial distress in the next few years of operation but had a somewhat solid performance during the last 90 days. Equity ratings for Capricor Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 13th of February 2007 | Category Healthcare | Classification Health Care |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. The company was founded in 2005 and is headquartered in San Diego, California. The company has 45.47 M outstanding shares of which 5.28 M shares are currently shorted by private and institutional investors with about 2.33 trading days to cover. More on Capricor Therapeutics
Moving together with Capricor Stock
Moving against Capricor Stock
Capricor Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | Karen Krasney | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCapricor Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Capricor Therapeutics' financial leverage. It provides some insight into what part of Capricor Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Capricor Therapeutics (CAPR) is traded on NASDAQ Exchange in USA. It is located in 10865 Road to the Cure, San Diego, CA, United States, 92121 and employs 101 people. Capricor Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 866.66 M. Capricor Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 45.47 M outstanding shares of which 5.28 M shares are currently shorted by private and institutional investors with about 2.33 trading days to cover.
Capricor Therapeutics currently holds about 51.42 M in cash with (25.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.11.
Check Capricor Therapeutics Probability Of Bankruptcy
Ownership AllocationCapricor Therapeutics holds a total of 45.47 Million outstanding shares. Capricor Therapeutics shows 16.72 percent of its outstanding shares held by insiders and 18.51 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Capricor Ownership Details
Capricor Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 158.4 K | |
| Partner Fund Management Lp | 2024-09-30 | 152.8 K | |
| Ghost Tree Capital, Llc | 2024-09-30 | 125 K | |
| Stempoint Capital Lp | 2024-09-30 | 93.6 K | |
| Schonfeld Strategic Advisors Llc | 2024-09-30 | 90.4 K | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 89.3 K | |
| Boothbay Fund Management, Llc | 2024-09-30 | 87.8 K | |
| Ubs O'connor Llc | 2024-09-30 | 82.9 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 82.7 K | |
| Blackrock Inc | 2024-06-30 | 1.6 M | |
| Vanguard Group Inc | 2024-09-30 | 1.6 M |
Capricor Therapeutics Historical Income Statement
Capricor Stock Against Markets
Capricor Therapeutics Corporate Management
| Deborah Ascheim | Chief Medical Officer | Profile | |
| Kristi Elliott | Chief Officer | Profile | |
| Xavier Avat | Chief Officer | Profile | |
| MD FACC | Executive Board | Profile | |
| Catherine Kelleher | Consultant | Profile | |
| Eduardo Marbn | CoFounder Board | Profile |
Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.